Scalper1 News
Sandoz, the generics division of Novartis (NVS), and its biotech partner Momenta Pharmaceuticals won FDA approval on Thursday for the first generic version of popular multiple-sclerosis drug Copaxone. The FDA denied a citizens’ petition by Copaxone’s manufacturer, Teva Pharmaceutical Industries (TEVA), requesting further proof of the similarity and safety of any generic version of the drug. Momenta (MNTA) said in a press release that the generic Scalper1 News
Scalper1 News